Enhancement of endogenous defenses against ROS by supra-nutritional level of selenium is more safe and effective than antioxidant supplementation in reducing hypertensive target organ damage

Medical Hypotheses

Volumn 68, Issue 5, 2007, Pages 952-956

  Zhou, Xin ^a,b   Ji, Wen Jie ^c   Zhu, Yong ^b   He, Bing ^b   Li, He ^b   Huang, Ti Gang ^a   Li, Yu Ming ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; C REACTIVE PROTEIN; REACTIVE OXYGEN METABOLITE; SELENIUM;

ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; DIET SUPPLEMENTATION; DRUG MEGADOSE; HAIR LOSS; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; NAIL DISEASE; ORGAN INJURY; OXIDATION KINETICS; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; VITAMIN SUPPLEMENTATION;

ANTIOXIDANTS; DIETARY SUPPLEMENTS; HUMANS; HYPERTENSION; MODELS, BIOLOGICAL; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SELENIUM; TREATMENT OUTCOME;

EID: 33847016407     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.09.058     Document Type: Article

References (47)

1. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., and He J. Global burden of hypertension: analysis of worldwide data. Lancet 365 9455 (2005) 217-223
2. Mensah G.A., Croft J.B., and Giles W.H. The heart, kidney, and brain as target organs in hypertension. Curr Probl Cardiol 28 2 (2002) 156-193
3. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics - 2006 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation. 2006;113(6):85-151.
4. Chiuve S.E., McCullough M.L., Sacks F.M., and Rimm E.B. Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications. Circulation 114 2 (2006) 160-167
5. Zarraga I.G., and Schwarz E.R. Impact of dietary patterns and interventions on cardiovascular health. Circulation 114 9 (2006) 961-973
6. Gongora M.C., Qin Z., Laude K., et al. Role of extracellular superoxide dismutase in hypertension. Hypertension 48 3 (2006) 473-481
7. Zhu X.Y., Daghini E., Chade A.R., et al. Role of oxidative stress in remodeling of the myocardial microcirculation in hypertension. Arterioscler Thromb Vasc Biol 26 8 (2006) 1746-1752
8. Ulker S., McMaster D., McKeown P.P., and Bayraktutan U. Impaired activities of antioxidant enzymes elicit endothelial dysfunction in spontaneous hypertensive rats despite enhanced vascular nitric oxide generation. Cardiovasc Res 59 2 (2003) 488-500
9. Vaziri N.D. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 13 1 (2004) 93-99
10. Nagotani S., Hayashi T., Sato K., et al. Reduction of cerebral infarction in stroke-prone spontaneously hypertensive rats by statins associated with amelioration of oxidative stress. Stroke 36 3 (2005) 670-672
11. Giugliano D., Ceriello A., and Esposito K. The effects of diet on inflammation: emphasis on the metabolic syndrome. J Am Coll Cardiol 48 4 (2006) 677-685
12. Estruch R., Martinez-Gonzalez M.A., Corella D., et al. Effects of a mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med 145 1 (2006) 1-11
13. Houston M.C. Nutraceuticals, vitamins, antioxidants, and minerals in the prevention and treatment of hypertension. Prog Cardiovasc Dis 47 6 (2005) 396-449
14. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The alpha-tocopherol, beta carotene cancer prevention study group. N Engl J Med 1994;330(15):1029-35.
15. Lichtenstein AH, Appel LJ, Brands M, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American heart association nutrition committee. Circulation 2006;114(1):82-96.
16. Lee I.M., Cook N.R., Gaziano J.M., et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's health study: a randomized controlled trial. JAMA 294 1 (2005) 56-65
17. Vivekananthan D.P., Penn M.S., Sapp S.K., Hsu A., and Topol E.J. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 361 9374 (2003) 2017-2023
18. Miller E.R., Pastor-Barriuso III R., Dalal D., Riemersma R.A., Appel L.J., and Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142 1 (2005) 37-46
19. Ingold K.U., Bowry V.W., Stocker R., and Walling C. Autoxidation of lipids and antioxidation by alpha-tocopherol and ubiquinol in homogeneous solution and in aqueous dispersions of lipids: unrecognized consequences of lipid particle size as exemplified by oxidation of human low density lipoprotein. Proc Natl Acad Sci USA 90 1 (1993) 45-49
20. Schneider C. Chemistry and biology of vitamin E. Mol Nutr Food Res 49 1 (2005) 7-30
21. Stadtman T.C. Selenocysteine. Annu Rev Biochem 65 1 (1996) 83-100
22. Thomson C.D. Assessment of requirements for selenium and adequacy of selenium status: a review. Eur J Clin Nutr 58 3 (2004) 391-402
23. Saito Y., Yoshida Y., Akazawa T., Takahashi K., and Niki E. Cell death caused by selenium deficiency and protective effect of antioxidants. J Biol Chem 278 41 (2003) 39428-39434
24. Bruno R.S., Leonard S.W., Atkinson J., et al. Faster plasma vitamin E disappearance in smokers is normalized by vitamin C supplementation. Free Radic Biol Med 40 4 (2006) 689-697
25. Rayman M.P. The importance of selenium to human health. Lancet 356 9225 (2000) 233-241
26. Rayman M.P., and Rayman M.P. The argument for increasing selenium intake. Proc Nutr Soc 61 2 (2002) 203-215
27. Kang Y.J. The antioxidant function of metallothionein in the heart. Proc Soc Exp Biol Med 222 3 (1999) 263-273
28. Cai L., Klein J.B., and Kang Y.J. Metallothionein inhibits peroxynitrite-induced DNA and lipoprotein damage. J Biol Chem 275 50 (2000) 38957-38960
29. Bobillier-Chaumont S., Maupoil V., and Berthelot A. Metallothionein induction in the liver, kidney, heart and aorta of cadmium and isoproterenol treated rats. J Appl Toxicol 26 1 (2006) 47-55
30. Oshima Y., Fujio Y., Nakanishi T., et al. STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart. Cardiovasc Res 65 2 (2005) 428-435
31. Wang J., Song Y., Elsherif L., et al. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 113 4 (2006) 544-554
32. Fang C.X., Dong F., Ren B.H., Epstein P.N., and Ren J. Metallothionein alleviates cardiac contractile dysfunction induced by insulin resistance: role of AKT phosphorylation, PTB1B, PPAR gamma and c-Jun. Diabetologia 48 11 (2005) 2412-2421
33. Wang L., Zhou Z., Saari J.T., and Kang Y.J. Alcohol-induced myocardial fibrosis in metallothionein-null mice: prevention by zinc supplementation. Am J Pathol 167 2 (2005) 337-344
34. Kang Y.J., Chen Y., Yu A., Voss-McCowan M., and Epstein P.N. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J Clin Invest 100 6 (1997) 1501-1506
35. Fang C.X., Doser T.A., Yang X., Sreejayan N., and Ren J. Metallothionein antagonizes aging-induced cardiac contractile dysfunction: role of PTP1B, insulin receptor tyrosine phosphorylation and AKT. Aging Cell 5 2 (2006) 177-185
36. Yang X., Doser T.A., Fang C.X., et al. Metallothionein prolongs survival and antagonizes senescence-associated cardiomyocyte diastolic dysfunction: role of oxidative stress. FASEB J 20 7 (2006) 1024-1026
37. Cohen N., and Golik A. Zinc balance and medications commonly used in the management of heart failure. Heart Fail Rev 11 1 (2006) 19-24
38. Aydemir T.B., Blanchard R.K., and Cousins R.J. Zinc supplementation of young men alters metallothionein, zinc transporter, and cytokine gene expression in leukocyte populations. Proc Natl Acad Sci USA 103 6 (2006) 1699-1704
39. Liu Y, Jiang GQ, Ru BG, Xu ZL, Guo JH. Quantification of metallothionein induced with selenium by using competitive ELISA. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao. Shanghai 2002;34(2):245-247.
40. Wei W.Q., Abnet C.C., Qiao Y.L., et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. Am J Clin Nutr 79 1 (2004) 80-85
41. Liu D., Liu S., Huang Y., Liu Y., Zhang Z., and Han L. Effect of selenium on human myocardial glutathione peroxidase gene expression. Chin Med J (Engl) 113 9 (2000) 771-775
42. Hussein O., Rosenblat M., Refael G., and Aviram M. Dietary selenium increases cellular glutathione peroxidase activity and reduces the enhanced susceptibility to lipid peroxidation of plasma and low-density lipoprotein in kidney transplant recipients. Transplantation 63 5 (1997) 679-685
43. Salonen J.T., Alfthan G., Huttunen J.K., Pikkarainen J., and Puska P. Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study. Lancet 2 8291 (1982) 175-179
44. Suadicani P., Hein H.O., and Gyntelberg F. Serum selenium concentration and risk of ischaemic heart disease in a prospective cohort study of 3000 males. Atherosclerosis 96 1 (1992) 33-42
45. Blankenberg S., Rupprecht H.J., Bickel C., et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 349 17 (2003) 1605-1613
46. Salvini S., Hennekens C.H., Morris J.S., Willett W.C., and Stampfer M.J. Plasma levels of the antioxidant selenium and risk of myocardial infarction among US physicians. Am J Cardiol 76 17 (1995) 1218-1221
47. Witte K.K., Nikitin N.P., Parker A.C., et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J 26 21 (2005) 2238-2244